Although a longer duration of trastuzumab treatment of 24 months seems to add toxicity without additional survival benefit 3 , the shorter duration of a 9-week trastuzumab regimen only exhibited a borderline significant improvement in DFS 4 .
← all excerpts
Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer.
1
—
—